Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 3,092 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Completed No phase listed Observational

Simple Versus Radical Hysterectomy for Stage I Cervical Cancer

NCT00506376
View directory record Official record
Conditions
Cervical Cancer
Interventions
Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 10, 2026, 4:59 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

NCT00500240
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Insulin Glargine, Insulin Aspart
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 10, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

NCT01180959
View directory record Official record
Conditions
Liver Cancer
Interventions
Bevacizumab, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 10, 2026, 4:59 PM EDT
Recruiting No phase listed Observational

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

NCT05046080
View directory record Official record
Conditions
Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
Interventions
Electronic Health Record Review, Laboratory Biomarker Analysis
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 10, 2026, 4:59 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

International Ovarian & Testicular Stromal Tumor Registry

NCT01970696
View directory record Official record
Conditions
Ovarian Sex-cord Stromal Tumor, Testicular Stromal Tumors, Ovarian Small Cell Carcinoma
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
0 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 10, 2026, 4:59 PM EDT
Active, not recruiting Not applicable Interventional

NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer

NCT04986670
View directory record Official record
Conditions
Lung Cancer, Small Cell, Lung Cancer Metastatic, Lung Cancer Recurrent, Treatment Side Effects, Lung Cancer, Non-small Cell, Nutritional Imbalance
Interventions
Nutritional Counseling, Medically Tailored Meals (MTMs), Nutrition Prescription, Nutrition Assessment, Nutrition Toolkit, Monthly Emails
Behavioral · Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 100 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 10, 2026, 4:59 PM EDT
Active, not recruiting Phase 2 Interventional

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

NCT02689440
View directory record Official record
Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions
Dasatinib, Laboratory Biomarker Analysis, Venetoclax
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2040
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 10, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers

NCT02964182
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma, Tobacco-Related Carcinoma
Interventions
Cigarette, Nicotine Replacement, Questionnaire Administration, Survey Administration, Very Low Nicotine Content Cigarette, ECIG-Hi, ECIG-Lo
Drug · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 10, 2026, 4:59 PM EDT
Terminated Phase 4 Interventional

Natrecor in Pulmonary Hypertension

NCT00075179
View directory record Official record
Conditions
Pulmonary Hypertension, Cancer, Lung Disease, Cardiothoracic Surgery
Interventions
Nesiritide (Natrecor), Right Heart Catheterization
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 10, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

NCT02129062
View directory record Official record
Conditions
Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions
Ibrutinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 10, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional

Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma

NCT01636388
View directory record Official record
Conditions
Hodgkins Lymphoma
Interventions
allogeneic donor derived LMP specific cytotoxic T-lymphocyte
Biological
Lead sponsor
New York Medical College
Other
Eligibility
Up to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 10, 2026, 4:59 PM EDT
Active, not recruiting Early Phase 1 Interventional

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

NCT03943173
View directory record Official record
Conditions
BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions
Chemotherapy, Olaparib, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 10, 2026, 4:59 PM EDT
Completed No phase listed Observational

Mastectomy Reconstruction Outcomes Consortium (MROC) Study

NCT01723423
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
4,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Savannah, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 10, 2026, 4:59 PM EDT
Terminated Phase 1Phase 2 Interventional

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT04550442
View directory record Official record
Conditions
Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
Interventions
Azacitidine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 10, 2026, 4:59 PM EDT
Recruiting No phase listed Observational

Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer

NCT02107105
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage I Rectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 10, 2026, 4:59 PM EDT
Completed Phase 1 Interventional

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

NCT00431054
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Perifosine, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 10, 2026, 4:59 PM EDT
Active, not recruiting Not applicable Interventional

Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices

NCT05124405
View directory record Official record
Conditions
Cancer, Diabetes
Interventions
Fitbit, Continuous Glucose Monitor
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 10, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma

NCT00432445
View directory record Official record
Conditions
Retinoblastoma
Interventions
Proton Beam Radiation Therapy, Ophthalmic EUA
Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 10, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

NCT00750737
View directory record Official record
Conditions
Invasive Fungal Infections, Hematologic Malignancies
Interventions
Posaconazole, ABLC
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 10, 2026, 4:59 PM EDT
Recruiting Not applicable Interventional

Immediate Lymphatic Reconstruction After Lymphadenectomy in Melanoma Patients: a Parallel Cohort Pilot Study

NCT06887205
View directory record Official record
Conditions
Lymphatic Reconstruction, Lymphadenectomy
Interventions
Lymphovenous bypass (LVB)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 10, 2026, 4:59 PM EDT
Completed No phase listed Observational

Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer

NCT05058339
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Hematologic Malignancy, Recurrent Malignant Solid Neoplasm
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 10, 2026, 4:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT02953561
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Avelumab, Azacitidine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 10, 2026, 4:59 PM EDT
Active, not recruiting Phase 2 Interventional

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

NCT04171622
View directory record Official record
Conditions
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Squamous Cell Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions
Lenvatinib, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 10, 2026, 4:59 PM EDT
Completed Not applicable Interventional Results available

Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy

NCT01099202
View directory record Official record
Conditions
Leukemia
Interventions
Procrit (epoetin alfa)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2012 · Synced Oct 10, 2026, 4:59 PM EDT